ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
Notable Friday Option Activity: IIPR, HUMA, ANAB
Noteworthy Wednesday Option Activity: ANAB, UNH, RBLX
Wednesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Wednesday?
Which stocks are experiencing notable movement on Wednesday?
Wednesday Sector Laggards: Shipping, Drugs
Relative Strength Alert For AnaptysBio
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Gap analysis on 2024-12-11: gap up and gap down stocks in today's session.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate...
Noteworthy Monday Option Activity: ANAB, WLY, WNS
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Participation in November and December Investor Conferences
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for...
Noteworthy Thursday Option Activity: ANAB, ASTS, CWK
Notable Monday Option Activity: ANAB, AIR, FTI
Anaptys Announces Participation in September Investor Conferences
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
Noteworthy Wednesday Option Activity: TPR, AMRK, ANAB
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the second quarter of 2024.A...
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA...